Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus decitabine versus decitabine in intermediate-2 and high-risk myelodysplastic syndrome
ChiCTR1900028440Phase 2Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Decitabine with Camrelizumab + decitabine (2 arms). Primary endpoint: overall response rate. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
camrelizumabdecitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1900028440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028440.